Patrick Daly

DocwireNews

Authors of the EXHALE study evaluated the safety and efficacy of dexpramipexole for treating patients with eosinophilic asthma. The study&rsquo;s lead author, Salman Siddiqui, BM, FRCP, PhD, highlighted a need for new and effective oral treatments for asthma, and that dexpramipexole had not yet been evaluated.According to the article, published in&nbsp;The Journal of Allergy and Clinical Immunology, dexpramipexole effectively lowered asthma and blood absolute eosinophil count (AEC), and demonstrated a favorable tolerability profile among patients with moderate-to-severe <a href="https://docwirenews.com/post/benralizumab-in-real-world-severe-eosinophilic-asthma">uncontrolled eosinophilic asthma</a>.The double-blinded, proof-of-concept randomized controlled trial randomized 103 participants with AECs &ge;300/&mu;L dexpramipexole 37.5 mg (n=22), 75 mg (n=26), 150 mg (n=28), or placebo (n=27) twice-daily. Treatments were administered for 12 weeks.The primary end point of analysis was relative change in AEC from baseline to week 12. Secondary and exploratory end points were changes from baseline in pre-bronchodilator Forced Expiratory Volume over 1 second (FEV1) and nasal eosinophil peroxidase, respectively.<h3>Is Dexpramipexole Effective in Eosinophilic Asthma?</h3>Researchers found dexpramipexole significantly reduced the placebo-corrected week 12 to baseline AEC ratio in patients with moderate-to-severe uncontrolled eosinophilic asthma.Specifically, the dexpramipexole 150 mg group had a 77% reduction (ratio, 0.23; 95% CI, 0.12-0.43; P&lt;.0001), and the 75 mg group had a 66% reduction (ratio, 0.34; 95% CI, 0.18-0.65;&nbsp;P=.0014).The <a href="https://clinicaltrials.gov/ct2/show/NCT05763121" target="_blank" rel="noopener">EXHALE</a> investigators also reported that dexpramipexole reduced the week 12 to baseline nasal eosinophil peroxidase ratio in the 150 mg group (median reduction, 0.11; P=.020) and 75 mg group (median reduction, 0.17;&nbsp;P=.021). Authors added that non-significant placebo-corrected improvements in pre-bronchodilator FEV1 were observed starting at week 4.Overall, Dr. Siddiqui and colleagues suggested that oral, twice-daily dexpramipexole in patients with eosinophilic asthma effectively lowered eosinophil counts compared with placebo and was well-tolerated.Read More <a href="https://docwirenews.com/page/asthma">Recent News and Expert Interviews in Asthma</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Dexpramipexole: Exploring More Oral Asthma Treatments

Asthma

In the EXHALE trial, Dexpramipexole significantly lowered eosinophil counts compared with placebo in patients with eosinophilic asthma.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe